These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 14709967)

  • 21. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic parameters of bromperidol in Korean subjects.
    Lee SY; Kim YG; Kim HG; Kim JW
    Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extrapyramidal symptoms and flunarizine.
    Amery WK
    Funct Neurol; 1987; 2(3):363-4. PubMed ID: 3692277
    [No Abstract]   [Full Text] [Related]  

  • 24. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis].
    Savel'eva MI; Sychev DA; Kazakov RE; Ignat'ev IV; Tishenova A; Gasanov NA; Ramenskaia GV; Kukes VG
    Klin Med (Mosk); 2008; 86(11):22-8. PubMed ID: 19177788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Gillman PK
    Hum Psychopharmacol; 2005 Jan; 20(1):61-2; author reply 63-4. PubMed ID: 15614840
    [No Abstract]   [Full Text] [Related]  

  • 27. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
    Sjöqvist F; Eliasson E
    Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
    Vaz RJ; Nayeem A; Santone K; Chandrasena G; Gavai AV
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3816-20. PubMed ID: 15993593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Terbinafine and potential drug interactions.
    Kaplan DL
    J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):882-4. PubMed ID: 11050604
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
    Venkatakrishnan K; Obach RS
    Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: cyp2d6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling.
    Zhu W; Mantione KJ; Shen L; Cadet P; Esch T; Goumon Y; Bianchi E; Sonetti D; Stefano GB
    Med Sci Monit; 2005 Nov; 11(11):BR397-404. PubMed ID: 16258388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
    Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol.
    Hellum BH; Nilsen OG
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):350-8. PubMed ID: 17910620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
    Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
    Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
    O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
    J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acyclovir induced extrapyramidal symptoms : letter to editor.
    Handa SK; Das CP; Prabhakar S
    Neurol India; 2002 Mar; 50(1):109-10. PubMed ID: 11960170
    [No Abstract]   [Full Text] [Related]  

  • 38. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
    Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
    Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
    Le Bourdonnec B; Ajello CW; Seida PR; Susnow RG; Cassel JA; Belanger S; Stabley GJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
    Bioorg Med Chem Lett; 2005 May; 15(10):2647-52. PubMed ID: 15863335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.